Nyxoah S.A. (NYXH)
USD 6.12
(1.75%)
USD 6.12
(1.75%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -43.21 Million EUR | -38.39% |
| 2022 | -31.22 Million EUR | -13.06% |
| 2021 | -27.61 Million EUR | -125.55% |
| 2020 | -12.24 Million EUR | -68.78% |
| 2019 | -7.25 Million EUR | 20.09% |
| 2018 | -9.07 Million EUR | 12.46% |
| 2017 | -10.37 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -11.9 Million EUR | -9.3% |
| 2024 Q2 | -13.12 Million EUR | -10.23% |
| 2023 Q1 | -11.91 Million EUR | 10.42% |
| 2023 Q3 | -7.61 Million EUR | 40.52% |
| 2023 Q2 | -12.79 Million EUR | -7.44% |
| 2023 FY | -43.21 Million EUR | -38.39% |
| 2023 Q4 | -10.89 Million EUR | -43.1% |
| 2022 Q2 | -4.99 Million EUR | 25.53% |
| 2022 Q1 | -6.7 Million EUR | -7.25% |
| 2022 FY | -31.22 Million EUR | -13.06% |
| 2022 Q3 | -6.24 Million EUR | -25.05% |
| 2022 Q4 | -13.29 Million EUR | -113.08% |
| 2021 Q2 | -6.93 Million EUR | -22.4% |
| 2021 Q3 | -8.76 Million EUR | -26.27% |
| 2021 FY | -27.61 Million EUR | -125.55% |
| 2021 Q4 | -6.24 Million EUR | 28.69% |
| 2021 Q1 | -5.66 Million EUR | -42.71% |
| 2020 Q3 | -3.97 Million EUR | -150.95% |
| 2020 Q1 | -2.38 Million EUR | -1752.14% |
| 2020 FY | -12.24 Million EUR | -68.78% |
| 2020 Q4 | -3.97 Million EUR | 0.0% |
| 2020 Q2 | -1.58 Million EUR | 33.49% |
| 2019 Q3 | -128.5 Thousand EUR | 92.79% |
| 2019 Q4 | -128.5 Thousand EUR | 0.0% |
| 2019 Q2 | -1.78 Million EUR | 0.0% |
| 2019 FY | -7.25 Million EUR | 20.09% |
| 2019 Q1 | -1.78 Million EUR | 0.0% |
| 2018 FY | -9.07 Million EUR | 12.46% |
| 2017 FY | -10.37 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -63.32 Million USD | 31.759% |
| AngioDynamics, Inc. | -184.34 Million USD | 76.56% |
| AtriCure, Inc. | -30.43 Million USD | -41.967% |
| Avinger, Inc. | -18.32 Million USD | -135.873% |
| Azenta, Inc. | -14.25 Million USD | -203.093% |
| BioLife Solutions, Inc. | -66.42 Million USD | 34.948% |
| The Cooper Companies, Inc. | 294.2 Million USD | 114.688% |
| Daxor Corporation | 280.64 Thousand USD | 15497.662% |
| Ekso Bionics Holdings, Inc. | -15.19 Million USD | -184.327% |
| Femasys Inc. | -14.24 Million USD | -203.303% |
| GlucoTrack, Inc. | -7.09 Million USD | -508.877% |
| Harvard Bioscience, Inc. | -3.41 Million USD | -1165.359% |
| Hologic, Inc. | 789.5 Million USD | 105.473% |
| ICU Medical, Inc. | -29.65 Million USD | -45.716% |
| Intuitive Surgical, Inc. | 1.79 Billion USD | 102.403% |
| KORU Medical Systems, Inc. | -13.74 Million USD | -214.474% |
| LeMaitre Vascular, Inc. | 30.1 Million USD | 243.538% |
| Innovative Eyewear, Inc. | -6.66 Million USD | -548.495% |
| Innovative Eyewear, Inc. | -6.66 Million USD | -548.495% |
| Masimo Corporation | 81.5 Million USD | 153.021% |
| Microbot Medical Inc. | -10.74 Million USD | -302.346% |
| Meihua International Medical Technologies Co., Ltd. | 11.62 Million USD | 471.703% |
| Merit Medical Systems, Inc. | 94.41 Million USD | 145.77% |
| Nephros, Inc. | -1.57 Million USD | -2643.619% |
| NovoCure Limited | -207.04 Million USD | 79.129% |
| NEXGEL, Inc. | -3.15 Million USD | -1268.768% |
| NEXGEL, Inc. | -3.15 Million USD | -1268.768% |
| Singular Genomics Systems, Inc. | -94.82 Million USD | 54.427% |
| OraSure Technologies, Inc. | 53.65 Million USD | 180.537% |
| Pro-Dex, Inc. | 2.12 Million USD | 2131.594% |
| Pulse Biosciences, Inc. | -42.21 Million USD | -2.374% |
| Predictive Oncology Inc. | -13.98 Million USD | -209.011% |
| Precision Optics Corporation, Inc. | -2.95 Million USD | -1364.13% |
| QuidelOrtho Corporation | -10.1 Million USD | -327.842% |
| Repligen Corporation | 41.57 Million USD | 203.932% |
| Sanara MedTech Inc. | -4.3 Million USD | -904.184% |
| STAAR Surgical Company | 21.34 Million USD | 302.427% |
| Sharps Technology, Inc. | -9.84 Million USD | -339.073% |
| Utah Medical Products, Inc. | 16.63 Million USD | 359.766% |
| DENTSPLY SIRONA Inc. | -132 Million USD | 67.264% |
| Jin Medical International Ltd. | 2.87 Million USD | 1601.339% |